Magenta Therapeutics Analyst Ratings
Magenta Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 12/21/2022 | 506.06% | BTIG | $6 → $3 | Maintains | Buy |
| 08/25/2022 | 304.04% | Goldman Sachs | → $2 | Downgrades | Buy → Neutral |
| 05/24/2022 | 304.04% | Goldman Sachs | $3 → $2 | Maintains | Buy |
| 04/18/2022 | 1112.12% | BTIG | $10 → $6 | Maintains | Buy |
| 04/18/2022 | 1516.16% | Mizuho | $17 → $8 | Maintains | Buy |
| 01/24/2022 | 1112.12% | B. Riley Securities | $13 → $6 | Maintains | Buy |
| 01/06/2022 | 1516.16% | Goldman Sachs | $7 → $8 | Upgrades | Neutral → Buy |
| 08/03/2021 | 1314.14% | JP Morgan | $16 → $7 | Downgrades | Overweight → Neutral |
| 06/29/2021 | 3940.4% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 3940.4% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/18/2021 | 4142.42% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 01/07/2021 | 3132.32% | Mizuho | → $16 | Initiates Coverage On | → Buy |
| 06/08/2020 | 2930.3% | Goldman Sachs | → $15 | Upgrades | Neutral → Buy |
| 12/06/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/06/2019 | 3536.36% | Goldman Sachs | → $18 | Assumes | → Neutral |
| 03/25/2019 | 3132.32% | Goldman Sachs | $17 → $16 | Downgrades | Buy → Neutral |
| 03/15/2019 | — | Raymond James | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 3536.36% | Goldman Sachs | → $18 | Initiates Coverage On | → Buy |
| 07/16/2018 | 3536.36% | JP Morgan | → $18 | Initiates Coverage On | → Overweight |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 4344.44% | Wedbush | → $22 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月26日 | - | 韋德布什 | 評級下調 | 跑贏→中性 | |
| 2022年12月21日 | 506.06% | BTIG | $6→$3 | 維護 | 買 |
| 2022年08月25日 | 304.04% | 高盛 | →$2 | 評級下調 | 購買→中性 |
| 2022年05月24日 | 304.04% | 高盛 | $3→$2 | 維護 | 買 |
| 04/18/2022 | 1112.12% | BTIG | $10→$6 | 維護 | 買 |
| 04/18/2022 | 1516.16% | 瑞穗 | $17→$8 | 維護 | 買 |
| 01/24/2022 | 1112.12% | B.萊利證券 | $13→$6 | 維護 | 買 |
| 01/06/2022 | 1516.16% | 高盛 | $7→$8 | 升級 | 中性→購買 |
| 08/03/2021 | 1314.14% | 摩根大通 | $16→$7 | 評級下調 | 超重→中性 |
| 2021/06/29 | 3940.4% | 康託·菲茨傑拉德 | →$20 | 開始承保 | →超重 |
| 2021/06/15 | 3940.4% | BTIG | →$20 | 開始承保 | →購買 |
| 2021/05/18 | 4142.42% | B.萊利證券 | →$21 | 開始承保 | →購買 |
| 01/07/2021 | 3132.32% | 瑞穗 | →$16 | 開始承保 | →購買 |
| 06/08/2020 | 2930.3% | 高盛 | →$15 | 升級 | 中性→購買 |
| 2019年6月12日 | - | BTIG | 開始承保 | →購買 | |
| 2019年6月12日 | 3536.36% | 高盛 | →$18 | 假設 | →中性 |
| 2019年03月25日 | 3132.32% | 高盛 | $17→$16 | 評級下調 | 購買→中性 |
| 2019年03月15日 | - | 雷蒙德·詹姆斯 | 開始承保 | →跑贏大盤 | |
| 2018年07月16日 | 3536.36% | 高盛 | →$18 | 開始承保 | →購買 |
| 2018年07月16日 | 3536.36% | 摩根大通 | →$18 | 開始承保 | →超重 |
| 2018年07月16日 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2018年07月16日 | 4344.44% | 韋德布什 | →$22 | 開始承保 | →跑贏大盤 |
What is the target price for Magenta Therapeutics (MGTA)?
品紅治療公司(MGTA)的目標價格是多少？
The latest price target for Magenta Therapeutics (NASDAQ: MGTA) was reported by Wedbush on January 26, 2023. The analyst firm set a price target for $0.00 expecting MGTA to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
韋德布什於2023年1月26日報道了品紅治療公司(納斯達克：MGTA)的最新目標價。這家分析公司將目標價定為0.00美元，預計MGTA將在12個月內下跌(跌幅可能為-100.00%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Magenta Therapeutics (MGTA)?
洋紅色治療公司(MGTA)的最新分析師評級是多少？
The latest analyst rating for Magenta Therapeutics (NASDAQ: MGTA) was provided by Wedbush, and Magenta Therapeutics downgraded their neutral rating.
馬京塔治療公司(納斯達克代碼：MGTA)的最新分析師評級由韋德布什提供，馬京塔治療公司下調了其中性評級。
When is the next analyst rating going to be posted or updated for Magenta Therapeutics (MGTA)?
Magenta治療公司(MGTA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Magenta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Magenta Therapeutics was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與洋紅治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Magenta治療公司的上一次評級是在2023年1月26日提交的，所以你應該預計下一次評級將在2024年1月26日左右的某個時候提供。
Is the Analyst Rating Magenta Therapeutics (MGTA) correct?
分析師對洋紅治療公司(MGTA)的評級正確嗎？
While ratings are subjective and will change, the latest Magenta Therapeutics (MGTA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Magenta Therapeutics (MGTA) is trading at is $0.50, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的洋紅治療公司(MGTA)評級被下調，目標價為0.00美元至0.00美元。目前洋紅色治療公司(MGTA)的交易價格為0.50美元，超出了分析師的預測範圍。